title: Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation andCEP110-FGFR1Rearrangement.
abstract: This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) withCEP110-FGFR1rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation.The Oncologist2017;22:480-483.
authors.affiliation: Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Marc
authors.initials: M
authors.lastname: Wehrli
authors.affiliation: Division of Hematology, Inselspital University Hospital Bern, Bern, Switzerland.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Oppliger Leibundgut
authors.affiliation: Seefeldstrasse 45, 8008, Zurich, Switzerland.
authors.forename: Heinrich H
authors.initials: HH
authors.lastname: Gattiker
authors.affiliation: Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Markus G
authors.initials: MG
authors.lastname: Manz
authors.affiliation: Division of Hematology, University Hospital Zurich, Zurich, Switzerland antoniamaria.mueller@usz.ch.
authors.forename: Antonia M S
authors.initials: AM
authors.lastname: Müller
authors.affiliation: Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Jeroen S
authors.initials: JS
authors.lastname: Goede
mesh_terms: D018797:Cell Cycle Proteins / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D000069439:Dasatinib / Q000008:administration & dosage; D004314:Down Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D007955:Leukemoid Reaction / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011788:Quality of Life; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000235:genetics*; D014178:Translocation, Genetic / Q000235:genetics
chemical_list: C474898:CNTRL protein, human; D018797:Cell Cycle Proteins; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; C496348:FGFR1 protein, human; D051496:Receptor, Fibroblast Growth Factor, Type 1; D000069439:Dasatinib
keywords: Acute myeloid leukemia; CEP110‐FGFR1 fusion protein; Dasatinib; Eosinophilia; Imatinib